Clinical trials group Icon, whose primary listing is on Nasdaq, has reported strong second-quarter figures, with net income rising to $2.7 million (#2.88 million) from $2 million last year, while sales were 48 per cent higher on $28.6 million. "Our second quarter was another very good quarter for Icon. Record levels of net revenue and net profit were again achieved and the volume of potential business opportunities remained very strong," said chairman Dr Ronan Lambe.